c
x
chart
exchange
Terminal
Flow
Screener
Markets
Trends
Premium
Alerts
EST
UTC-5 New York
Blue Chip
Log in
Sign up
GCGR
General Catalyst Global Resilience Merger Corp. Class A
stock
NASDAQ
EOD
Nov 13, 2026 4:00:00 PM EST
9.995
USD
-0.050%
(-0.005)
34
Pre-market
After-hours
Overview
Company
Exchanges
Shorts
News
News
GCGR News
1
/
1
Nov 2, 2026
Day breaks
Nov 17, 2026
04:10 AM EST
Ascletis Submits IND Application to the U.S. FDA for ASC36_37o FDC, a Potentially First-in-Class Once-Weekly Oral Quadruple Peptide Agonist Targeting Amylin Receptor, GLP-1R, GIPR and GCGR, for the Treatment of Obesity
·
PR Newswire
+1 source
Nov 16, 2026
04:10 AM EST
Ascletis Highlights Oral and Long-Acting Injectable Anti-Obesity Preclinical Studies at ObesityWeek® 2026
·
PR Newswire
+1 source
Nov 13, 2026
10:48 PM EST
Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List
·
PR Newswire
Nov 11, 2026
04:10 AM EST
Ascletis Submits IND Application to the U.S. FDA for ASC30_39 FDC, a Potentially First-in-Class Oral Small Molecule Fixed-Dose Combination of GLP-1R Agonist and Selective Amylin Receptor Agonist, for the Treatment of Obesity
·
PR Newswire
Nov 2, 2026
03:50 AM EST
Ascletis to Present Study Results of Oral Small Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Peptide Agonist ASC37 at ObesityWeek® 2026
·
PR Newswire
Oct 28, 2026
07:40 PM EDT
Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes
·
PR Newswire
Oct 25, 2026
08:10 PM EDT
Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity
·
PR Newswire
Oct 22, 2026
08:10 PM EDT
Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
·
PR Newswire
Oct 19, 2026
08:10 PM EDT
Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity
·
PR Newswire
Oct 5, 2026
05:53 AM EDT
Micot's XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal Disease
·
ACN Newswire
Oct 2, 2026
05:00 AM EDT
Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026
·
PR Newswire
Sep 28, 2026
08:00 PM EDT
Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
·
PR Newswire